BTIG Maintains Buy on Humacyte, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 53.5%

Neg 53.5% Neu 0% Pos 0%

BTIG analyst Ryan Zimmerman maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $6 to $3.

Comments

No comments yet. Be the first!